Prognostic factors in ALS: A critical review

Amyotrophic Lateral Sclerosis

Volumn 10, Issue 5-6, 2009, Pages 310-323

  Chiò, Adriano ^a   Logroscino, Giancarlo ^b   Hardiman, Orla ^c   Swingler, Robert ^d   Mitchell, Douglas ^e   Beghi, Ettore ^f   Traynor, Bryan G ^g  

^a UNIVERSITY OF TURIN   (Italy)

^b HARVARD UNIVERSITY   (United States)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e ROYAL PRESTON HOSPITAL   (United Kingdom)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Amyotrophic lateral sclerosis; Prognostic factors; Survival; Trials

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; PLACEBO; RILUZOLE; SURVIVAL MOTOR NEURON PROTEIN 2;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; COGNITION; DEMOGRAPHY; DISEASE COURSE; ENTERIC FEEDING; FAMILY HISTORY; HUMAN; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RESPIRATORY FUNCTION; REVIEW; SOCIAL PSYCHOLOGY; SURVIVAL; SYSTEMATIC REVIEW;

AGE OF ONSET; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; NUTRITIONAL STATUS; PROGNOSIS; PROSPECTIVE STUDIES; RESPIRATION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 70450180994     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960802566824     Document Type: Review

References (108)

1. Armon C.Motor Neuron Disease. In: , eds. Gorelick PB Alter M editors. Handbook of Neuroepidemiology. New York: Marcel Dekker; 1994. pp 407-54.
2. Albert SM, Murphy PL, Del Bene ML, Rowland LP. A prospective study of p and actual treatment choices in ALS. Neurology. 1999;53:278-83.
3. Miller RG, Munsat TL, Swash M, Brooks BR. for theWorld Federation of Neurology Committee on Research. Consensus guidelines for the design and implementation of clinical trials in ALS. J Neurol Sci. 1999;169:2-12.
4. Borasio GD. Amyotrophic lateral sclerosis: Lessons in trial design from recent trials. J Neurol Sci. 1997;152(Suppl 1):S23-8.
5. Lai EC, Flice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. and the North America ALS/IGF-I Study Group. Effect of recombinant human insulin-like growth factor-1 on progression of ALS. A placebo controlled study. Neurology. 1997;49:1621-30.
6. Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, et al. A placebo-controlled trial of insulin-like growth factor-1 in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology. 1998;51:583-6.
7. Italian ALS Study Group. Branched chain amino acids and amyotrophic lateral sclerosis: A treatment failure? Neurology. 1993;43:2466-70.
8. Norris F, Sheperd R, Denys E, U K, Mukai E, Elias L, Holden D, Norris H. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci. 1993;118:48-55.
9. Caroscio JT, Calhoun WF, Yahr MD. Prognostic factors in motor neuron disease: A prospective study of longevity. In: Rose FC, editor. Research progress in motor neuron disease. London: Pitman, 1984. p. 34-43.
10. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118:707-19.
11. Preux P-M, Couratier P, Boutros-Toni F, Salle J-Y, Tarabaud F, Bernet-Bernady P, et al. Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors. Neuroepidemiology. 1996;15:153-60.
12. Louwerse ES Visser CE Bossuyt PMM Weverling GJ and the Netherlands ALS Consortium. Amyotrophic lateral sclerosis: Mortality risk during the course of the disease and prognostic factors. J Neurol Sci. 1997;152 (Suppl 1): S10-7.
13. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 2002;3:15-21.
14. Testa D, Lovati R, Ferrarini M, Salmoiraghi F, Filippini G. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotrophic Lateral Sclerosis. 2004;5:208-12.
15. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotrophic Lateral Sclerosis. 2005;6:37-44.
16. Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology. 1998;50:66-72.
17. Lee JR, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. Lett Neurol Sci. 1995;132:207-15.
18. Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-9.
19. Yoshida S, Mulder DW, Kurland LT, Chu C-P, Okazaki H. Follow-up study on amyotrophic lateral sclerosis in Rochester, Minnesota 1925 through 1984. Neuroepidemiology. 1986;5:61-70.
20. Christensen PB, Hoier-Pedersen E, Jensen BN. Survival of patients with amyotrophic lateral sclerosis in two Danish counties. Neurology. 1990;40:600-4.
21. Tysnes O-B, Vollset SE, Larsen JP, Aarli JA. Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology. 1994;13:226-35.
22. Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology. 2002;59:280-2.
23. Chancellor AM, Slattery JM, Frazer H, Swingler RJ, Holloway SM, Wallow CP. The prognosis of adult-onset motor neuron disease: A prospective study based on the Scottish Motor Neuron Disease Register. J Neurol. 1993; 240:339-46.
24. Traynor BJ, Codd BM, Corr B, ForDe C, Frost E, Hardiman O. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria. Arch Neurol. 2000;57:1171-6.
25. Chiò A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al. for the Piemonte and Valle d'Aosta Register for ALS. Early symptom progression rate is related to ALS outcome: A prospective population-based study. Neurology. 2002;59:99-103. (Pubitemid 34742801)
26. Del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, Van Belle G. Prognosis in amyotrophic lateral sclerosis. A population-based study. Neurology. 2003;60:813-9.
27. Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology. 2005; 25:114-9.
28. Armon C, Moses D. Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials. J Neurol Sci. 1998;160(Suppl 1):S37-41.
29. Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: Early predictors of prolonged survival. J Neurol. 2006;253:1428-36.
30. Forbes RB, Colville S, Cran GW, Swingler RJ. Unexpected decline in survival from amyotrophic lateral sclerosis/motor neuron disease. J Neurol Neurosurg Psychiatry. 2004; 75:1753-5.
31. Forbes RB Colville S Swingler RJ for the Scottish ALS/ MND Register. The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 years or above. Age Ageing. 2004;33:131-4.
32. Uebayashi Y, Yase Y, Tnaka H, Shimada Y, Toyokura Y. Prognosis of motor neuron disease in Japan. Neuroepidemiology. 1983;2:243-56.
33. Lopez-Vega JM, Calleja J, Combarros O, Polo JM, Berciano J. Motor neuron disease in Cantabria. Acta Neurol Scand. 1988;77:1-5.
34. Marti-Fabregas J, Fredas J, Illa I. Prognostic factors in amyotrophic lateral sclerosis. Neurologia. 1996;11:174-81.
35. Tysnes O-B, Vollset SE, Aarli JA. Epidemiology of amyotrophic lateral sclerosis in Hordaland county, western Norway. Acta Neurol Scand. 1991;83:280-5.
36. Bourke SC, Tomlison M, Wlliams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: A randomized controlled trial. Lancet Neurology. 2006;5:140-7.
37. De Carvalho M, Matias T, Coelho F, Evangelista T, Pinto A, Luís ML. Motor neuron disease presenting with respiratory failure. J Neurol Sci. 1996;139 (Suppl):117-22.
38. Shoesmith CL, Findlater K, Rowe A, Strong MJ. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatr. 2007;78:629-31.
39. Magnus T, Beck M, Giess R, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: Predictors of survival. Muscle Nerve. 2002;25:709-14.
40. Thijs V, Peeters E, Theys P, Matthijs G, Robberecht W. Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population. Acta Neurol Belg. 2000;100:84-90.
41. Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRS-R predicts survival time in an ALS clinic population. Neurology. 2005;64:38-43.
42. Beghi E Millul A Logroscino G Vitelli E Micheli A SLALOM GROUP. Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9:163-7.
43. Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, et al. Epidemiology of mutations in superoxiDe dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997;41:210-21.
44. Aggarwal A, Nicholson G. Age-dependent penetrance of three different superoxiDe dismutase 1 (SOD1) mutations. Int J Neurosci. 2005;115:1119-30.
45. Juneja T, Pericak-Vance MA, Laing NG, Dave S, Siddique T. Prognosis in familial amyotrophic lateral sclerosis: Progression and survival in patients with glu100gly and ala4val mutations in Cu/Zn superoxiDe dismutase. Neurology. 1997;48:55-7.
46. Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the Cu/Zn superoxiDe dismutase gene. Curr Neurol Neurosci Reports. 2006;6:36-47.
47. Armon C, Graves MC, Moses D, Forte DK, Sepulveda L, Darby SM, Smith RA. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2000;23:874-82.
48. Bryan WW, Hoagland RJ, Murphy J, Armon C, Barohn RJ, Goodpasture JC, et al. and the rhCNTF ALS Study Group. Can we eliminate placebo in Amyotrophic Lateral Sclerosis clinical trials? Amyotrophic Lateral Sclerosis. 2002;4:11-5.
49. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265-7.
50. Kollewe K Mauss U Krampfl K Petri S Dengler R Mohammadi BALSFRS-R score and its ratio: A useful predictor for ALS progression. J Neurol Sci. 2008 (Epub ahead of print).
51. Armon C, Brandstater ME. Motor unit number estimatebased rates of progression of ALS predict patient survival. Muscle Nerve. 1999;22:1571-5.
52. De Carvalho M, Scotto M, Lopes A, Swash M. Quantitating progression in ALS. Neurology. 2005;64:1783-5.
53. McDonald E, Wiedenfeld SA, Hillel A, Carpenter CL, Walter RA. Survival in amyotrophic lateral sclerosis. The role of psychological factors. Arch Neurol. 1994;51:17-23.
54. Johnston M, Earll A, Giles M, McClenahan R, Stevens D, Morrison V. Mood as a predictor of disability and survival in patients diagnosed with ALS/MND. Br J Health Psychol. 1999;4:127-36.
55. Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: Current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol. 1998;24:104-17.
56. Olney RK, Murphy J, Forshew D, Garwood E, Miller BL, Langmore S, et al. The effects of executive and behavioural dysfunction on the course of ALS. Neurology. 2005;65: 1774-7.
57. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology. 2003;60:1094-7.
58. Rippon GA, Scarmeas N, Gordon PH, Murphy PL, Albert SM,Mitsumoto H, et al. An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol. 2006;63:345-52.
59. Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999;53:1059-63.
60. Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, et al. The natural history of amyotrophic lateral sclerosis. Neurology. 1993;43:1316-22.
61. Czaplinsli A, Yen AA, Appel SH. Forced vital capacity (FCV) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:390-2.
62. Schiffman PL, Belsh JM. Pulmonary function at diagnosis of ALS: Rate of deterioration. Chest. 1993;103:508-13.
63. Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J. Respiratory muscle strength and ventilatory failure in ALS. Brain. 2001;124:200-13.
64. Schmid EP, Drachman DB, Wiener CM, Clawson L, Kimball L, Lechtzin N. Pulmonary predictors of survival in amyotrophic lateral sclerosis: Use in clinical trial design. Muscle Nerve. 2006;33:127-32.
65. Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve. 1989;12:833-41.
66. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial clinical limits of amyotrophic lateral sclerosis workshop contributors. J Neurol Sci. 1994;124(Suppl):96-107.
67. Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A. Prolonged survival in motor neuron disease: A descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry. 2003;74:995-7.
68. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis. A population-based study in Ireland, 1996-2000. J Neurol. 2003;250:473-9. (Pubitemid 36459755)
69. Mitchell JD, O'Brien MR, Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2006;7:67-77.
70. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007;Jan 24(1):D001447.
71. Mathus-Vliegen LMH, Louwersee LS, Merkus MP, Tytgat GNJ, De Jong JMBV. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc. 1994;40:463-9.
72. Chiò A Finocchiaro E Meineri P Bottacchi E Schiffer D and the ALS Percutaneous Endoscopic Gastrostomy Study Group. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology. 1999;53:1123-5.
73. Forbes RB, Colville S, Swingler RJ. Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neuron disease. A record linkage study from the Scottish Motor Neurone Disease Register. J Neurol. 2004;251:813-7.
74. Heffernan C, Jenkinson C, Holmes T, Feder G, Kupfer R, Leigh PN, et al. Nutritional management in MND/ALS patients: An evidence based review. Amyotroph Lateral Scler Other Motor Neuron Dis. 2004;5:72-83.
75. Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luis ML. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: Survival rates in a controlled trial. J Neurol Sci. 1995;129 (Suppl):19-26.
76. Pinto A, De Carvalho M, Evangelista T, Lopes A, Sales-Luís L. Nocturnal pulse oximetry: A new approach to establish the appropriate time for non-invasive ventilation in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:31-5.
77. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: A population based study, 1996-2000. J Neurol Neurosurg Psychiatr. 2003;74: 1258-61.
78. Chiò A, Bottacchi E, Buffa C, Mutani R, Mora G. PARALS. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77:948-50.
79. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Lepore V, et al. ALS multidisciplinary clinic and survival: Results from a population-based study in southern Italy. J Neurol. 2007;254:1107-12. (Pubitemid 47353403)
80. Siddique T, Pericak-Vance MA, Caliendo J, Hong ST, Hung WY, Kaplan J, et al. Lack of association between apolipoprotein E genotype and amyotrophic lateral sclerosis. Neurogenetics. 1998;1:213-6.
81. Lacomblez L, Doppler V, Beucler I, Costes G, Salachas F, Raisonner A, et al. APOE: A potential marker of disease progression in ALS. Neurology. 2002;58:1112-4.
82. Veldink JH, Van Den Berg LH, Cobben JM, Stulp RP, De Jong JMBV, Vogels OJ, et al. Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS. Neurology. 2001;56:753-7.
83. Gamez J, Barcelo MJ, Munoz X, Xarmona F, Cusco I, Baiget M, et al. Survival and respiratory decline are not related to homozygous SMN2 deletions in ALS patients. Neurology. 2002;59:1456-60.
84. Jokic N, Gonzalez De Aguilar JL, Pradat PF, Dupuis L, Echaniz-Laguna A, Muller A, et al. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol. 2005;57:553-6.
85. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidaemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004-9.
86. Kalra S, Vitale A, Cashman NR, Genge A, Arnold DL. Cerebral degeneration predicts survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2006;77:1253-5.
87. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, et al. for the SLAP registry. Predictors of delay in the diagnosis and clinical entry of amyotrophic lateral sclerosis patients: A population based study. J Neurol Sci. 2006;250:45-9.
88. De Carvalho M, Scotto M, Lopes A, Swash M. Quantitating progression in ALS. Neurology. 2005;64:1783-5.
89. Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology. 1993;43:751-5.
90. Altman DG, Bland JM. Treatment allocation by minimization. Br Med J. 2005;330:853.
91. Treasure T, MacRae KD. Minimization: The platinum standard for trials. Br Med J. 1998;317:363.
92. Schwid RS, Cutter GR. Futility studies: Spending a little to save a lot. Neurology. 2006;66:626-7.
93. Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006;66:660-3.
94. Rosen AD. Amyotrophic lateral sclerosis: Clinical features and prognosis. Arch Neurol. 1978;35:638-42.
95. Kondo K, Hemmi I. Clinical statistics of 515 fatal cases of motor neuron disease. Neuroepidemiology. 1984;3:129-48.
96. Chiò A, Brignolio F, Leone M, Mortara P, Rosso MG, Tribolo A, Schiffer D. A survival analysis of 155 cases of progressive muscular atrophy. Acta Neurol Scand. 1985; 72:407-13.
97. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis: A study of its presentation and prognosis. J Neurol. 1985;232:295-300.
98. Chiò A, Brignolio F, Meineri P, Schiffer D. Phenotypic and genotypic heterogeneity of dominantly inherited amyotrophic lateral sclerosis. Acta Neurol Scand. 1987;75: 277-82.
99. Eisen A, Schulzer M, MacNeil M, Pant B, Mak E. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve. 1993;16:27-32. (Pubitemid 23014301)
100. Mandrioli J, Faglioni P, Nichelli P, Sola P. Amyotrophic lateral sclerosis: Prognostic indicators of survival. Amyotroph Lateral Scler. 2006;7:211-20.
101. Czaplinski A, Yen AA, Simpson EP, Appel SH. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: Is the natural history of amyotrophic lateral sclerosis changing? Arch Neurol. 2006;63:1139-43.
102. Kristensen O, Melgaard B. Motor neuron disease: Prognosis and epidemiology. Acta Neurol Scand. 1977;56:299-308.
103. Forsgren L, Almay BG, Holmgren G, Wall S. Epidemiology of motor neuron disease in northern Sweden. Acta Neurol Scand. 1983;68:20-9.
104. Mortara P, Chiò A, Rosso MG, Leone M, Schiffer D. Motor neuron disease in the province of Turin, Italy, 1966-1980. Survival analysis in an unselected population. J Neurol Sci. 1984;66:165-73.
105. Granieri E, Carreras M, Tola R, Paolino E, Tralli G, Eleopra R, Serra G. Motor neuron disease in the province of Ferrara, Italy, 1964-1982. Neurology. 1988;38:1604-8.
106. Bettoni L, Bazzani M, Bortone E, Descola I, Pisani E, Mancia D. Steadiness of amyotrophic lateral sclerosis in the province of Parma, Italy, 1960-1990. Acta Neurol Scand. 1994;90:276-80.
107. Alcaz S, Jarebinski M, Pekmezovic T, Stevic-Marinkovic Z, Pavlovic S, Apolstoski S. Epidemiological and clinical characteristics of ALS in Belgrade, Yugoslavia. Acta Neurol Scand. 1996;94:264-8.
108. Argyriou AA, Polychromatopoulos P, Papapetropolous S, Ellul J, Andriopoulos I, Katsoulas G, et al. Clinical and epidemiological features of motor neuron disease in southwestern Greece. Acta Neurol Scand. 2005;111:108-13.